HOLON, Israel, Oct. 24,
2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a
clinical-stage cancer immunotherapy company and a leader in
predictive target discovery, announced today that the Company will
release its third quarter 2018 financial results on Wednesday, November 7, 2018 before the U.S.
financial markets open. Management will host a live webcast to
review the results and provide a corporate update at 8:30 AM ET.
To access the live conference call by telephone, please dial
1-888-407-2553 from the U.S.,
or +972-3-918-0644 internationally. The call will also be available
via live webcast through Compugen's website, located at the
following link. Following the live audio webcast, a replay will be
available on the Company's website.
About Compugen
Compugen is a clinical-stage, therapeutic discovery and
development company utilizing its broadly applicable predictive
discovery infrastructure to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered, including T
cell immune checkpoints and myeloid target programs. Compugen's
business model is to selectively enter into collaborations for its
novel targets and related drug product candidates at various stages
of research and development. The Company is headquartered in
Israel with R&D facilities in
both Israel and South San Francisco, CA. Compugen's ordinary
shares are listed on Nasdaq and the Tel Aviv Stock Exchange under
the ticker symbol CGEN. For additional information, please visit
Compugen's corporate website at www.cgen.com.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124
Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: 212-213-0006
View original
content:http://www.prnewswire.com/news-releases/compugen-third-quarter-2018-conference-call-scheduled-for-wednesday-november-7-2018-at-830-am-et-300736904.html
SOURCE Compugen Ltd.